Wedbush analyst David Nierengarten lowered the firm’s price target on 2seventy Bio to $22 from $26 and keeps an Outperform rating on the shares. The firm looks forward to color around competitive dynamics in the MM market when 2seventy Bio reports earnings on or before August 14, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TSVT: